{ "schemaVersion": 2, "eyebrow": "Addiction Medicine", "title": "Alcohol Withdrawal Medication Selection", "summary": "Select benzodiazepines for most alcohol withdrawal, reserve phenobarbital for protocolized severe or benzodiazepine-refractory presentations, and avoid substituting adjunctive agents for seizure- and delirium-preventive therapy.", "seoDescription": "Practical medication selection for alcohol withdrawal: benzodiazepines, phenobarbital, adjuncts, seizure management, and monitoring decisions.", "clinicalQuestion": "Which medications should clinicians select for alcohol withdrawal across uncomplicated, severe, seizure-associated, and benzodiazepine-refractory presentations?", "specialty": "Addiction Medicine", "audience": "U.S. physicians and medical trainees", "tags": [ "alcohol withdrawal syndrome", "benzodiazepines", "phenobarbital", "CIWA-Ar", "alcohol withdrawal seizure", "delirium tremens" ], "keyTakeaways": [ "Benzodiazepines remain first-line therapy because they alleviate withdrawal discomfort and prevent alcohol-withdrawal seizures and delirium. [16]", "Use a long-acting benzodiazepine when feasible; favor shorter-acting agents when hepatic metabolism is impaired or in older adults. [16]", "Do not use antipsychotics alone to manage alcohol withdrawal, and use benzodiazepines rather than anticonvulsants after an alcohol-withdrawal seizure. [16]", "Phenobarbital is a reasonable protocolized alternative or adjunct in severe or benzodiazepine-nonresponsive withdrawal, but combination therapy requires close sedation and respiratory monitoring. [12][13][23]", "CIWA-Ar requires patient participation; use an objective sedation/agitation assessment rather than CIWA-Ar when communication is unreliable. [7][12]" ], "sections": [ { "id": "choose-treatment-setting", "eyebrow": "Initial branch", "heading": "Choose medication after identifying severe or complicated withdrawal", "intro": "Medication choice should follow risk and monitoring capacity rather than symptom score alone.", "paragraphs": [ "Treat alcohol-withdrawal seizures, delirium, marked autonomic instability, or inability to safely receive and report symptom-triggered therapy as complicated withdrawal requiring monitored acute-care management. Withdrawal manifestations may begin within 8 hours of the last alcohol intake, peak at 24 to 72 hours, and occur alongside cardiopulmonary, infectious, arrhythmic, bleeding, and other medical complications that can change both drug selection and disposition. [12]", "Use CIWA-Ar only when the patient can reliably answer subjective questions and nursing reassessment can drive dosing. Dementia, language barriers, delirium, intubation, or other communication limitations make CIWA-Ar unreliable; in these settings, use a protocol based on objective bedside assessment, including a sedation/agitation scale when available, and select therapy that can be safely monitored in the care setting. [7][12]", "For patients whose clinical state may represent another process, do not attribute persistent delirium, hypoxemia, fever, focal neurologic findings, or hemodynamic instability to withdrawal alone. Evaluate and treat competing acute illness while treating withdrawal, because alcohol withdrawal commonly coexists with infection, cardiopulmonary insufficiency, arrhythmia, and bleeding disorders. [12]" ], "bullets": [ "Use symptom-triggered benzodiazepine dosing when patient reporting is reliable and repeated assessment is feasible. [8][9]", "Use scheduled or front-loaded benzodiazepine treatment when withdrawal is severe, symptom scoring is impractical, or rapid control is required in a monitored setting. [9]", "Limit the acute benzodiazepine course to the first 3 to 7 days after alcohol cessation, individualized to withdrawal severity and comorbidity. [16]" ], "subsections": [], "table": { "caption": "Medication-selection framework for acute alcohol withdrawal. [7][9][16][23]", "columns": [ "Clinical branch", "Preferred medication strategy", "What changes the next step" ], "rows": [ [ "Reliable communication; uncomplicated symptoms", "Symptom-triggered benzodiazepine regimen. [8][9][16]", "Escalating symptoms despite repeated doses, seizure, delirium, or inability to participate in CIWA-Ar warrants monitored protocol escalation. [7][9][16]" ], [ "Severe withdrawal or rapid symptom escalation", "Front-loaded treatment with a longer-acting benzodiazepine in a monitored setting. [9][16]", "Impaired hepatic metabolism or advanced age favors a shorter-acting benzodiazepine. [16]" ], [ "Benzodiazepine nonresponse, intolerance, or severe complex withdrawal", "Use phenobarbital as an alternative or adjunct within an institutional protocol and with respiratory/sedation monitoring. [6][9][12][23]", "Avoid unstructured accumulation of both agents; reassess for delirium, co-ingestions, and non-withdrawal causes of agitation. [12][23]" ], [ "Alcohol-withdrawal seizure", "Treat and prevent recurrent withdrawal seizures with a benzodiazepine. [16]", "Do not substitute an anticonvulsant for benzodiazepine therapy for recurrent alcohol-withdrawal seizure prevention. [16]" ], [ "Hallucinosis or agitation despite adequate withdrawal treatment", "An antipsychotic may be considered only as an adjunct to withdrawal-directed therapy. [16]", "Antipsychotic monotherapy is not appropriate because it does not replace seizure- and delirium-preventive treatment. [16]" ] ] } }, { "id": "benzodiazepine-selection", "eyebrow": "First-line therapy", "heading": "Select benzodiazepines for seizure and delirium prevention", "intro": "Benzodiazepines are the default pharmacologic treatment unless patient factors favor a protocolized alternative.", "paragraphs": [ "Use a benzodiazepine as first-line medication for clinically significant alcohol withdrawal. Benzodiazepines are recommended to relieve withdrawal discomfort and to prevent seizures and delirium; evidence reviews also found benzodiazepines more effective than placebo for reducing alcohol-withdrawal seizures. [11][14][16]", "Choose a long-acting agent when hepatic metabolism is preserved because long-acting benzodiazepines are generally preferred for alcohol withdrawal. When hepatic metabolism is impaired, including liver failure, or in older adults, choose a shorter-acting benzodiazepine rather than applying the long-acting preference without adjustment. [16]", "Use symptom-triggered treatment when serial assessment is dependable. One cited inpatient regimen used lorazepam 2 mg orally every 2 to 8 hours, while fixed tapering lorazepam began at 2 to 8 mg three times daily according to severity; these dosing examples should be embedded in a local protocol with reassessment for oversedation, respiratory compromise, and persistent withdrawal. [8]", "For severe withdrawal, use front-loaded dosing with a longer-acting benzodiazepine when monitoring is available. Do not prolong treatment merely because insomnia, anxiety, or tremor persists after the acute withdrawal window; treatment duration should be individualized but generally limited to 3 to 7 days after cessation. [9][16]" ], "bullets": [ "Prefer symptom-triggered therapy when the patient can participate in symptom assessment and nursing reassessment is available. [8][9]", "Use a scheduled taper when symptom-triggered assessment is not operationally safe or reliable. [8][9]", "After an alcohol-withdrawal seizure, continue benzodiazepine-based withdrawal treatment rather than relying on anticonvulsants for secondary prevention. [16]" ], "subsections": [ { "heading": "When benzodiazepine response is inadequate", "paragraphs": [ "Before labeling withdrawal as benzodiazepine-resistant, confirm that medication administration and reassessment are occurring at an interval appropriate to clinical deterioration, determine whether CIWA-Ar is valid, and assess for delirium or medical comorbidity driving agitation. Patients transitioned from benzodiazepines to phenobarbital because of nonresponse or medication adverse effects have been reported to improve, but this switch should occur through a monitored protocol rather than by indefinite benzodiazepine dose escalation. [6][7][12]" ], "bullets": [] } ], "table": { "caption": "Benzodiazepine strategy by patient characteristic. [8][9][16]", "columns": [ "Patient factor", "Medication decision", "Operational implication" ], "rows": [ [ "Preserved hepatic metabolism", "A long-acting benzodiazepine is generally preferred. [16]", "Individualize dose and duration to withdrawal severity and medical comorbidity. [16]" ], [ "Impaired hepatic metabolism or older age", "Favor a shorter-acting benzodiazepine. [16]", "Monitor closely for medication accumulation and sedation. [16]" ], [ "Reliable symptom reporting", "Use symptom-triggered treatment. [8][9]", "Reassess with a validated local workflow; CIWA-Ar is appropriate only when subjective responses are reliable. [7]" ], [ "Severe withdrawal", "Use front-loaded, longer-acting benzodiazepine treatment in a monitored setting. [9]", "Escalate monitoring when delirium, seizures, or respiratory risk is present. [12][16]" ] ] } }, { "id": "phenobarbital-selection", "eyebrow": "Alternative and adjunct", "heading": "When to use phenobarbital instead of or with benzodiazepines", "intro": "Phenobarbital is most useful when a protocolized approach is available for severe or difficult-to-control withdrawal.", "paragraphs": [ "Consider phenobarbital as an alternative to benzodiazepines or as an adjunct when severe withdrawal persists despite benzodiazepine treatment, when benzodiazepines cause problematic adverse effects, or when a structured critical-care or emergency-department protocol is available. Phenobarbital has been used both alone and with benzodiazepines, and systematic reviews describe similar or potentially improved outcomes versus alternative therapy, although severe withdrawal definitions and prospective randomized data remain limited. [6][12][13]", "For an emergency-department patient managed with a symptom-triggered lorazepam protocol, one randomized trial evaluated a single intravenous phenobarbital load of 10 mg/kg. Compared with lorazepam protocol alone, the phenobarbital-loaded group had fewer ICU admissions without an increased adverse-event rate; a subsequent retrospective replication did not find a statistically significant between-group difference. This supports phenobarbital loading as a protocol option, not as a universal replacement for benzodiazepines. [23]", "In mild-to-moderate withdrawal, phenobarbital did not outperform IV lorazepam plus oral chlordiazepoxide in a 44-patient randomized emergency-department study for effectiveness, emergency-department length of stay, admission, or symptoms 48 hours after discharge. Select phenobarbital for a clear clinical or operational advantage rather than routine use in every lower-acuity presentation. [23]", "The principal tradeoff is additive central nervous system and respiratory depression when phenobarbital is layered onto benzodiazepines. Use a defined loading and reassessment protocol, document all sedative exposure, and ensure the monitoring environment can detect oversedation and respiratory deterioration. Evidence syntheses characterize phenobarbital as generally well tolerated, but the evidence base includes small trials and observational studies. [12][13][23]" ], "bullets": [ "Reasonable use case: severe withdrawal with inadequate benzodiazepine response under close monitoring. [6][9][12]", "Reasonable use case: current or prior severe, complex polysubstance withdrawal when a phenobarbital protocol is available. [9]", "Do not use phenobarbital plus benzodiazepines casually in an unmonitored setting because both are sedative-hypnotic therapies and combination regimens require monitoring. [12][23]" ], "subsections": [ { "heading": "Monotherapy versus adjunctive phenobarbital", "paragraphs": [ "Both phenobarbital monotherapy and phenobarbital-plus-benzodiazepine pathways are described. Adjunctive therapy may have additive symptomatic benefit in severe withdrawal, while phenobarbital's long half-life can provide an auto-tapering effect over the acute withdrawal phase; however, select one explicit institutional pathway and avoid combining approaches without a cumulative-dose and monitoring plan. [9][12][23]" ], "bullets": [] } ], "table": { "caption": "Practical phenobarbital decisions in alcohol withdrawal. [6][9][12][13][23]", "columns": [ "Scenario", "Phenobarbital role", "Evidence-informed limitation" ], "rows": [ [ "Mild-to-moderate emergency-department withdrawal", "May be used, but routine superiority over lorazepam plus chlordiazepoxide was not demonstrated. [23]", "Use benzodiazepines as standard first-line treatment unless a protocol-specific reason favors phenobarbital. [16][23]" ], [ "Severe withdrawal receiving symptom-triggered lorazepam", "A single IV phenobarbital 10 mg/kg load has been studied as adjunctive therapy. [23]", "One trial found fewer ICU admissions; retrospective replication was not statistically different. [23]" ], [ "Benzodiazepine nonresponse or intolerance", "Phenobarbital can be used as an alternative or transition therapy. [6][12]", "Use monitored dosing and reassess for other causes of persistent agitation or delirium. [12]" ], [ "Combined benzodiazepine and phenobarbital exposure", "May be effective in severe withdrawal. [13][23]", "Use only with a protocol that addresses cumulative sedation and respiratory monitoring. [12][23]" ] ] } }, { "id": "adjuncts-and-agents-to-avoid", "eyebrow": "Do not substitute", "heading": "Use adjunctive medications selectively and never instead of withdrawal-directed therapy", "intro": "Several agents may attenuate selected symptoms but do not displace benzodiazepines for complicated withdrawal.", "paragraphs": [ "Do not use antipsychotic medication as monotherapy for alcohol withdrawal. If hallucinations or severe agitation remain clinically dangerous after withdrawal-directed medication has been initiated, an antipsychotic may serve only as an adjunct; it does not provide the seizure- and delirium-preventive role of benzodiazepines. [16]", "Do not use anticonvulsants in place of benzodiazepines after an alcohol-withdrawal seizure. A review of 56 anticonvulsant studies involving 4,076 patients found no significant advantage over placebo for alcohol-withdrawal seizures, adverse events, or treatment discontinuation, even though carbamazepine reduced end-of-treatment CIWA-Ar scores more than benzodiazepines in some comparisons. [11][14][16]", "Carbamazepine and gabapentin may be considered as monotherapy for mild-to-moderate alcohol withdrawal in selected patients, but this limited role should not be extended to seizure-associated or delirious withdrawal. Carbamazepine has evidence for symptom-score reduction, whereas broader anticonvulsant evidence does not establish prevention of severe withdrawal outcomes. [5][9][11][16]", "Alpha-adrenergic agonists, beta-blockers, dexmedetomidine, and similar agents may be encountered as adjuncts for selected autonomic or agitation targets, but they are not substitutes for GABAergic withdrawal treatment. When using any adjunct, continue a benzodiazepine- or phenobarbital-based strategy that addresses seizure and delirium risk. [12][16]" ], "bullets": [ "Antipsychotic alone: avoid. [16]", "Anticonvulsant alone after withdrawal seizure: avoid. [16]", "Carbamazepine or gabapentin: restrict consideration to selected mild-to-moderate presentations, not complicated withdrawal. [5][9][11]", "Autonomic-symptom adjuncts: do not allow symptom suppression to obscure worsening withdrawal or replace seizure prophylaxis. [12][16]" ], "subsections": [], "table": { "caption": "Role of non-benzodiazepine medications in alcohol withdrawal. [5][9][11][12][16]", "columns": [ "Medication class", "Appropriate role", "Avoid or limitation" ], "rows": [ [ "Antipsychotics", "Adjunctive management of selected agitation or psychotic symptoms after withdrawal-directed treatment. [16]", "Do not use as stand-alone alcohol-withdrawal treatment. [16]" ], [ "Carbamazepine", "Potential option for selected mild-to-moderate withdrawal; may reduce CIWA-Ar scores. [5][9][11]", "Do not substitute for benzodiazepines after alcohol-withdrawal seizure. [16]" ], [ "Gabapentin", "May be used as monotherapy in mild-to-moderate withdrawal in selected patients. [9]", "Do not use as a replacement for benzodiazepines in seizure-associated or delirious withdrawal. [16]" ], [ "Other autonomic or sedating adjuncts", "May be used as adjuncts within monitored protocols. [12]", "Do not replace benzodiazepine or phenobarbital therapy directed at seizure and delirium prevention. [12][16]" ] ] } }, { "id": "monitoring-escalation-disposition", "eyebrow": "Reassessment", "heading": "Monitor response, detect oversedation, and transition after acute withdrawal", "intro": "Reassess both withdrawal control and medication toxicity after each treatment escalation.", "paragraphs": [ "At each reassessment, distinguish persistent withdrawal from medication toxicity and from an alternative cause of delirium. Worsening agitation despite treatment may indicate inadequate withdrawal control, but declining arousal or respiratory compromise after benzodiazepine or phenobarbital exposure should prompt immediate reassessment of additional sedative dosing and level of care. Phenobarbital and benzodiazepines are both used in ICU-level severe withdrawal pathways because close monitoring is central to safe escalation. [7][12][23]", "Escalate to higher-acuity monitoring for recurrent seizures, withdrawal delirium, uncontrolled agitation despite protocolized therapy, or clinically important respiratory/sedation risk after cumulative sedative treatment. Severe alcohol withdrawal has been associated with mechanical ventilation and longer ICU stays; studies of phenobarbital-containing regimens suggest potential reductions in these outcomes, but the populations and definitions vary. [12][13]", "Do not confuse completion of detoxification with treatment of alcohol use disorder. Supported withdrawal should be followed by treatment for alcohol dependence, and acute psychoactive medication should be dispensed in small quantities or under supervision when outpatient administration is used to reduce misuse risk. [16]" ], "bullets": [ "Reassess the validity of CIWA-Ar whenever delirium, impaired communication, or inability to cooperate develops. [7]", "After a seizure, use benzodiazepine treatment to prevent additional alcohol-withdrawal seizures. [16]", "Keep acute benzodiazepine treatment generally within 3 to 7 days after cessation, then transition to longitudinal alcohol-use-disorder care rather than continuing withdrawal medication. [16]" ], "subsections": [], "table": { "caption": "Reassessment triggers that change medication or monitoring. [7][12][13][16][23]", "columns": [ "Finding during treatment", "Immediate action", "Medication implication" ], "rows": [ [ "CIWA-Ar no longer reliable because of delirium or communication barrier", "Stop relying on subjective symptom-triggered scoring and use objective monitored assessment. [7]", "Use a protocol suitable for observed dosing and sedation monitoring. [7][12]" ], [ "Recurrent seizure", "Treat as complicated withdrawal in an acute-care setting. [16]", "Use benzodiazepines for prevention of further alcohol-withdrawal seizures. [16]" ], [ "Persistent severe symptoms despite benzodiazepines", "Confirm diagnosis and escalate through a monitored institutional pathway. [6][12]", "Consider phenobarbital alternative or adjunctive treatment. [6][9][12]" ], [ "Oversedation or respiratory deterioration after sedatives", "Withhold further empiric sedative escalation and increase monitoring. [12][23]", "Recalculate cumulative benzodiazepine and phenobarbital exposure before selecting the next dose. [12][23]" ] ] } } ], "faq": [ { "question": "Can carbamazepine replace benzodiazepines for an alcohol-withdrawal seizure?", "answer": "No. Benzodiazepines are recommended after an alcohol-withdrawal seizure to prevent recurrence; anticonvulsants should not replace them. Carbamazepine may have a limited role in selected mild-to-moderate withdrawal but has not established protection against severe withdrawal outcomes. [11][16]" }, { "question": "Should phenobarbital be added routinely to lorazepam?", "answer": "No. Adjunctive IV phenobarbital 10 mg/kg reduced ICU admissions in one randomized emergency-department study without more adverse events, but a retrospective replication found no statistically significant difference. Reserve combination therapy for a monitored, protocolized severe-withdrawal pathway. [23]" } ], "references": [ { "number": 1, "title": "Current evidence and clinical utility of phenobarbital for alcohol ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0953620523000845", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 2, "title": "Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0953620523000845", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 3, "title": "Efficacy and Safety of Anticonvulsants for the Inpatient Treatment of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/alcalc/article/57/2/155/6350883", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 4, "title": "The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review - COOPER - 2013 - Journal of Psychiatric and Mental Health Nursing - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2850.2012.01958.x", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 5, "title": "Trends in the Management of Inpatients With Alcohol... : Addictive Disorders & Their Treatment", "detail": "journals.lww.com", "url": "https://journals.lww.com/addictiondisorders/fulltext/2021/03000/trends_in_the_management_of_inpatients_with.4.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0735675709005348", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 7, "title": "Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0883944115005997", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "In hospitalized patients undergoing alcohol withdrawal, does ... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2016/10000/in_hospitalized_patients_undergoing_alcohol.31.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "Managing the Complex Intersection Between... : JACCP: Journal of the American College of Clinical Pharmacy", "detail": "journals.lww.com", "url": "https://journals.lww.com/02102005-202603000-00006", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 10, "title": "Clinical progress note : Journal Of Hospital Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/01445454-202510000-00010", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 11, "title": "[PDF] Alcohol-use disorders: physical complications Evidence Update ...", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg100/update/CG100/documents/cg100-alcoholuse-disorders-physical-complications-evidence-update2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 12, "title": "Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735736", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 13, "title": "[PDF] Appendix A: Summary of evidence from surveillance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg100/evidence/appendix-a-summary-of-evidence-from-surveillance-pdf-6659870510", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 14, "title": "[PDF] CG100: Alcohol-use disorders - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg115/documents/cg115-alcoholuse-disorders-diagnosis-assessment-and-management-of-harmful-drinking-and-alcohol-dependence-review-proposal2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 15, "title": "46 Phenobarbital Versus Benzodiazepines in Alcohol Withdrawal Syndrome: A Meta-Analysis - Annals of Emergency Medicine", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(23)00719-9/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com" }, { "number": 16, "title": "Mental Health, Brain Health and Substance Use", "detail": "www.who.int", "url": "https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/alcohol-use-disorders/management-of-alcohol-withdrawal", "authors": "www.who.int", "host": "www.who.int" }, { "number": 17, "title": "[PDF] NATIONAL INSTITUTE FOR HEALTH AND CARE ... - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg115/documents/alcohol-dependence-and-harmful-alcohol-use-surveillance-review-decision-cg100-and-cg115-alcohol-use-3", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 18, "title": "[PDF] Training manual for Clinical guidelines for withdrawal management ...", "detail": "iris.who.int", "url": "https://iris.who.int/server/api/core/bitstreams/13289816-ee2d-43b3-833f-afd838b7f591/content", "authors": "iris.who.int", "host": "iris.who.int" }, { "number": 19, "title": "[PDF] WHO mhGAP Guideline Update - IRIS", "detail": "iris.who.int", "url": "https://iris.who.int/server/api/core/bitstreams/6b9d19fe-b732-4065-bd2f-9736f4061a7e/content", "authors": "iris.who.int", "host": "iris.who.int" }, { "number": 20, "title": "Alcohol dependence | Treatment summaries - BNF - NICE", "detail": "bnf.nice.org.uk", "url": "https://bnf.nice.org.uk/treatment-summaries/alcohol-dependence", "authors": "bnf.nice.org.uk", "host": "bnf.nice.org.uk" }, { "number": 21, "title": "Matthew Sloan Remote Treatment of Alcohol Withdrawal Page 1 of ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/90/NCT04858490/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 22, "title": ": RP-503 - TEMPLATE PROTOCOL - ClinicalTrials.gov", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/05/NCT03846505/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 23, "title": "Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093658", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 24, "title": "The Effect of Phenobarbital on Excitatory Transmission in Alcohol Withdrawal Syndrome - Annals of Emergency Medicine", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(24)00216-6/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Current evidence and clinical utility of phenobarbital for alcohol ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0953620523000845", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "* Y Mo _et al._ ### Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials ### J Crit Care (2016) ### Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal ### Am J Emerg Med (2020) * M Carta _et al._ ### Ethanol wit", "score": 0.8080827 }, { "number": 2, "title": "Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0953620523000845", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "View more references\n\n## Cited by (10)\n\n ### Phenobarbital Versus Benzodiazepine-Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta-Analysis\n\n2026, Pharmacotherapy \n ### Managing the Complex Intersection Between Substance Use Disorders and I", "score": 0.78334314 }, { "number": 3, "title": "Efficacy and Safety of Anticonvulsants for the Inpatient Treatment of ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/alcalc/article/57/2/155/6350883", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal Mortality among patients with frequent emergency department use for alcohol-related reasons in Ontario: a population-based cohort study Double-blind comparative trial with carbamazepine vs diazepam ", "score": 0.7295395 }, { "number": 4, "title": "The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review - COOPER - 2013 - Journal of Psychiatric and Mental Health Nursing - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2850.2012.01958.x", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "# The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review. (1999) Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. (2006) Baclofen in the treatment", "score": 0.7077487 }, { "number": 5, "title": "Trends in the Management of Inpatients With Alcohol... : Addictive Disorders & Their Treatment", "detail": "journals.lww.com", "url": "https://journals.lww.com/addictiondisorders/fulltext/2021/03000/trends_in_the_management_of_inpatients_with.4.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Trends in the Management of Inpatients With Alcohol... : Addictive Disorders & Their Treatment\nThere are a variety of medications typically used for alcohol withdrawal syndrome (AWS) and the purpose of this study was to assess patterns of medication use for inpatients with an AWS. We then sea", "score": 0.68318754 }, { "number": 6, "title": "A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0735675709005348", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## Cited by (92)\n\nThe treatment of AWS in patients who are intolerant or nonresponsive to BZDs continues to plague our clinical management, and our current data shed light on this dilemma. Similar to others,20 we identified a small subset of 16 patients (3.8%) initially treated with BZDs and transit", "score": 0.6599319 }, { "number": 7, "title": "Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0883944115005997", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Ann Intensive Care\n\n### Intravenous phenobarbital for alcohol withdrawal and convulsions\n\n### Ann Emerg Med\n\n### Testing the reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic mixed studies review\n\n### Int J Nurs Stud\n\n### A prospective, randomized, trial ", "score": 0.65835214 }, { "number": 8, "title": "In hospitalized patients undergoing alcohol withdrawal, does ... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2016/10000/in_hospitalized_patients_undergoing_alcohol.31.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Symptom-triggered lorazepam treatment was 2 mg orally every 2 to 8 hours and fixed, tapering dosing of lorazepam started at 2 to 8 mg TID based on severity of", "score": 0.59344494 }, { "number": 9, "title": "Managing the Complex Intersection Between... : JACCP: Journal of the American College of Clinical Pharmacy", "detail": "journals.lww.com", "url": "https://journals.lww.com/02102005-202603000-00006", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "In patients with current or history of severe, complex polysubstance withdrawal, use of agents like phenobarbital can be helpful. Phenobarbital helps stabilize alcohol withdrawal and due to its long half-life, auto-tapers along the acute withdrawal phase and allows the ability to focus on other rapi", "score": 0.5663309 }, { "number": 10, "title": "Clinical progress note : Journal Of Hospital Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/01445454-202510000-00010", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Crossmark: Check for updates\n\n# Clinical progress note\n\n## Phenobarbital in the treatment of alcohol withdrawal syndrome\n\n## Related Articles\n\n## Readers Of this Article Also Read\n\n## Most Popular\n\nwk-ovid-logo\nprivacy policy options", "score": 0.3396748 }, { "number": 11, "title": "[PDF] Alcohol-use disorders: physical complications Evidence Update ...", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg100/update/CG100/documents/cg100-alcoholuse-disorders-physical-complications-evidence-update2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "by the Evidence Update reinforces or has potential to generate future change to the current guidance listed in the introduction. The relevant NICE guidance development centres have been made aware of this evidence which will be considered when guidance is reviewed. For further details of the evidenc", "score": 0.7429634 }, { "number": 12, "title": "Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735736", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Note. AWS = alcohol withdrawal syndrome; BID = twice daily; BZD = benzodiazepine; CDP = chlordiazepoxide; CI = confidence interval; CIWA-Ar = clinical institute withdrawal assessment score, revised; DZ = diazepam; ED = emergency department; GP = gabapentin; ICU = intensive care unit; IQR = interquar", "score": 0.7380092 }, { "number": 13, "title": "[PDF] Appendix A: Summary of evidence from surveillance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg100/evidence/appendix-a-summary-of-evidence-from-surveillance-pdf-6659870510", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "alcohol withdrawal syndrome. One systematic review (14) studying the effects of phenobarbital use with and without benzodiazepines for acute alcohol withdrawal (n=4 trials and 5 observational studies; n=720 patients) found that phenobarbital alone or in combination with benzodiazepines may provide s", "score": 0.69274646 }, { "number": 14, "title": "[PDF] CG100: Alcohol-use disorders - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg115/documents/cg115-alcoholuse-disorders-diagnosis-assessment-and-management-of-harmful-drinking-and-alcohol-dependence-review-proposal2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "did not show a benefit compared with other drugs. Anticonvulsants A second Cochrane review (including 56 studies, n=4076) for alcohol withdrawal indicated No GDG feedback was provided by the GDG questionnaire. No impact on recommendations. Benzodiazepines The updated Cochrane review identified by th", "score": 0.64344186 }, { "number": 15, "title": "46 Phenobarbital Versus Benzodiazepines in Alcohol Withdrawal Syndrome: A Meta-Analysis - Annals of Emergency Medicine", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(23)00719-9/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com", "snippet": "# 46 Phenobarbital Versus Benzodiazepines in Alcohol Withdrawal Syndrome: A Meta-Analysis. In drug-resistant alcohol withdrawal syndrome (AWS), numerous alternative agents to benzodiazepines have been investigated, and phenobarbital is one of them. * Intravenous phenobarbital for alcohol withdrawal ", "score": 0.629889 }, { "number": 16, "title": "Mental Health, Brain Health and Substance Use", "detail": "www.who.int", "url": "https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/alcohol-use-disorders/management-of-alcohol-withdrawal", "authors": "www.who.int", "host": "www.who.int", "snippet": "Benzodiazepines are recommended as front-line medication for the management of alcohol withdrawal in alleviating withdrawal discomfort, and preventing seizures and delirium. Long-acting benzodiazepines are recommended over shorter-acting ones, except in cases of impaired hepatic metabolism (e.g. liv", "score": 0.5863576 }, { "number": 17, "title": "[PDF] NATIONAL INSTITUTE FOR HEALTH AND CARE ... - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/cg115/documents/alcohol-dependence-and-harmful-alcohol-use-surveillance-review-decision-cg100-and-cg115-alcohol-use-3", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "use (CG115) New evidence was identified for the current 4 year surveillance review relating to the following clinical areas within the NICE guideline on alcohol dependence and harmful alcohol use. This guideline covers assessment, pharmacological interventions, psychological and psychosocial interve", "score": 0.5749443 }, { "number": 18, "title": "[PDF] Training manual for Clinical guidelines for withdrawal management ...", "detail": "iris.who.int", "url": "https://iris.who.int/server/api/core/bitstreams/13289816-ee2d-43b3-833f-afd838b7f591/content", "authors": "iris.who.int", "host": "iris.who.int", "snippet": "they must use a smaller amount than usual to reduce the risk of overdose. SUB-MODULE 4.3: WITHDRAWAL MANAGEMENT FOR BENZODIAZEPINE DEPENDENCE Benzodiazepines are central nervous system depressants. They are used to treat anxiety and sleeping disorders. When used appropriately, they are very effectiv", "score": 0.5373576 }, { "number": 19, "title": "[PDF] WHO mhGAP Guideline Update - IRIS", "detail": "iris.who.int", "url": "https://iris.who.int/server/api/core/bitstreams/6b9d19fe-b732-4065-bd2f-9736f4061a7e/content", "authors": "iris.who.int", "host": "iris.who.int", "snippet": "from alcohol compared to placebo. There were no serious side effects reported; however, baclofen can cause sedation and cessation of baclofen can be associated with a mild benzodiazepine-like withdrawal syndrome. Patients value affordable and available treatments for alcohol dependence. Baclofen is ", "score": 0.3746997 }, { "number": 20, "title": "Alcohol dependence | Treatment summaries - BNF - NICE", "detail": "bnf.nice.org.uk", "url": "https://bnf.nice.org.uk/treatment-summaries/alcohol-dependence", "authors": "bnf.nice.org.uk", "host": "bnf.nice.org.uk", "snippet": "Patients with mild alcohol dependence usually do not need assisted alcohol withdrawal. · A long-acting benzodiazepine, such as chlordiazepoxide hydrochloride or", "score": 0.29976124 }, { "number": 21, "title": "Matthew Sloan Remote Treatment of Alcohol Withdrawal Page 1 of ...", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/90/NCT04858490/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "of Structured Clinical Interview-DSM5 CIWA-AR: Clinical Institute Withdrawal Assessment for Alcohol-Revised CUDIT-R: Cannabis Use Disorder Identification Test-Revised FTND: Fagerstrom Test for Nicotine Dependence GAD-7: General Anxiety Disorder-7 PACS: Penn Alcohol Craving Scale PAWSS: Prediction of", "score": 0.6186197 }, { "number": 22, "title": ": RP-503 - TEMPLATE PROTOCOL - ClinicalTrials.gov", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/05/NCT03846505/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "J, Naranjo CA, Sellers EM. Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar). British Journal of Addiction. 1989;84(11):1353-1357. 140. Kubany ES, Leisen MB, Kaplan AS, et al. Development and preliminary validation of a brief broad-spe", "score": 0.39033696 }, { "number": 23, "title": "Management of Alcohol Withdrawal in the Emergency Department: Current Perspectives - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093658", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Finally, a systematic review of clinical trials examining the use of phenobarbital in the treatment of AWS concluded that the combination of phenobarbital with benzodiazepines seemed to have additive effects in the management of AWS symptoms and tended to be more effective for patients with severe A", "score": 0.7817479 }, { "number": 24, "title": "The Effect of Phenobarbital on Excitatory Transmission in Alcohol Withdrawal Syndrome - Annals of Emergency Medicine", "detail": "www.annemergmed.com", "url": "https://www.annemergmed.com/article/S0196-0644(24)00216-6/fulltext", "authors": "www.annemergmed.com", "host": "www.annemergmed.com", "snippet": "# The Effect of Phenobarbital on Excitatory Transmission in Alcohol Withdrawal Syndrome. Although we agree that phenobarbital can be an important adjunct in the management of patients with alcohol withdrawal syndrome, we challenge the contention that phenobarbital meaningfully inhibits glutaminergic", "score": 0.7318455 } ], "publishedAt": "2026-09-15T21:41:27.692578+00:00", "updatedAt": "2026-09-15T21:41:27.692578+00:00", "readingMinutes": 7, "slug": "alcohol-withdrawal-medication-selection" }